Ubi Pharma Inc is a Taiwan-based company mainly engaged in development and manufacturing of protein drugs and special dosage-form drugs. The Company is engaged in research and development, manufacturing and sales of protein drugs and special dosage-form drugs, contract manufacturing of pharmaceuticals, and provision of contract research services.

Employees

Sector

Pharmaceuticals

More about the company

End-of-day quote Taipei Exchange 06/05/2024			5-day change	1st Jan Change
14.25 ^TWD	+1.79%		-.--%	-

08-13	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-27	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	1.68B 53.13M 46.43M 43.64M 39.82M 74.74M 5.08B 74.75M 524M 202M 2.59B 200M 195M 8.36B	P/E 2024	-9.63x	P/E 2025	-5.68x
Enterprise Value	1.97B 62.25M 54.4M 51.13M 46.66M 87.57M 5.95B 87.58M 614M 237M 3.04B 234M 229M 9.8B	EV / Sales 2024	3.58x	EV / Sales 2025	3.83x
Free-Float	27.79%	Yield 2024 *	-	Yield 2025	-

08-13	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-27	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12/08/25	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/04/25	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
13/08/24	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
18/04/24	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
11/08/23	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
21/04/23	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
15/08/22	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	CI
29/04/22	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
29/04/22	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
16/08/21	Medigen Vaccine Biologics : Taiwan rejects COVID vaccine candidate, president to get domestic shot	RE
16/08/21	Medigen Vaccine Biologics : Taiwan denies approval for UBI's COVID-19 vaccine candidate	RE

3 years	10	38.5
5 years	10	114.53
10 years	8.34	288.72

UBI Pharma Inc. Stock

Stocks

6562

TW0006562002

Pharmaceuticals

Valuation: UBI Pharma Inc.

Latest news: UBI Pharma Inc.

Quotes and Performance

Price Extremes

Managers and Directors: UBI Pharma Inc.

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Jung Kuang Yang CEO	Chief Executive Officer	-	-
Meng Han Hsu DFI	Director of Finance/CFO	-	11/04/2016
Ying Yun Fan ADM	Chief Administrative Officer	-	01/03/2015

Director	Title	Age	Since
Ying Yun Fan BRD	Director/Board Member	-	30/06/2020
Yan Ning Kuo BRD	Director/Board Member	-	30/06/2020
Yao Hui Wei BRD	Director/Board Member	-	30/06/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
UBI PHARMA INC.	+1.79%	-.--%	-.--%	-55.05%	53.01M
ELI LILLY AND COMPANY	+0.63%	+2.86%	+54.80%	+112.27%	1,038B
JOHNSON & JOHNSON	-0.35%	+0.45%	+54.07%	+67.23%	649B
ABBVIE INC.	+0.26%	+0.83%	+19.15%	+73.64%	467B
ROCHE HOLDING AG	-0.19%	+0.97%	+34.30%	+45.99%	355B
NOVARTIS AG	+0.28%	+2.30%	+18.47%	+26.67%	269B
ASTRAZENECA PLC	+0.89%	+4.59%	+10.19%	+14.72%	260B
AMGEN INC.	+4.04%	+8.81%	+42.92%	+52.69%	213B
NOVO NORDISK A/S	-0.46%	-6.20%	-32.46%	-59.65%	176B
GILEAD SCIENCES, INC.	+1.39%	+4.34%	+35.70%	+103.50%	187B
Average	+0.83%	+1.38%	+23.71%	+38.20%	361.52B
Weighted average by Cap.	+0.50%	+1.47%	+36.19%	+66.93%

	2024	2025
Net sales	539M 17.01M 14.86M 13.97M 12.75M 23.93M 1.63B 23.93M 168M 64.69M 830M 63.87M 62.47M 2.68B	514M 16.24M 14.19M 13.34M 12.17M 22.84M 1.55B 22.85M 160M 61.77M 793M 60.98M 59.64M 2.56B
Net income	-175M -5.51M -4.81M -4.52M -4.13M -7.75M -527M -7.75M -54.3M -20.95M -269M -20.69M -20.23M -867M	-296M -9.35M -8.17M -7.68M -7.01M -13.16M -894M -13.16M -92.19M -35.57M -457M -35.12M -34.35M -1.47B
Net Debt	246M 7.78M 6.8M 6.39M 5.83M 10.94M 743M 10.94M 76.65M 29.58M 380M 29.2M 28.56M 1.22B	289M 9.12M 7.97M 7.49M 6.83M 12.83M 872M 12.83M 89.89M 34.69M 445M 34.24M 33.49M 1.44B